Related Experiment Video
Updated: Aug 8, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Diagnosis and management of MELAS
Madhav Thambisetty1, Nancy J Newman
1Department of Neurology, Institute of Psychiatry, King's College London, UK. MadhavT@iop.kcl.ac.uk
Abstract:
Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is the most common maternally inherited mitochondrial disease. An A-->G mutation in the transfer RNA(Leu(UUR)) gene at position 3243 of the mitochondrial DNA accounts for most MELAS cases. The transient nature of the stroke-like episodes is reflected in abnormalities on neuroimaging. The cardinal laboratory abnormalities include elevated serum lactate during the acute episodes and respiratory enzyme defects in skeletal muscle. Muscle biopsy also helps confirm the diagnosis by identifying abnormal proliferation of mitochondria. Although current treatment options for MELAS are largely supportive, several therapeutic approaches have been attempted with limited success. Genetic counseling is an important component of patient management in MELAS. Newer reproductive technologies hold promise for reducing the recurrence of MELAS in subsequent generations. Advances in research into gene therapy offer hope of treatment for the future.
Insights
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a common inherited condition. The A3243G mutation in mitochondrial DNA is a primary cause, with supportive treatments and genetic counseling being key management strategies.
Area of Science:
- Genetics
- Neurology
- Mitochondrial Biology
Background:
- Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is the most prevalent maternally inherited mitochondrial disorder.
- The A3243G mutation in the mitochondrial DNA's tRNA(Leu(UUR)) gene is responsible for the majority of MELAS cases.
- Clinical manifestations include transient stroke-like episodes, elevated serum lactate during acute phases, and skeletal muscle respiratory enzyme deficiencies.
Purpose of the Study:
- To summarize the key aspects of MELAS, including its genetic basis, clinical presentation, diagnostic methods, and current/future therapeutic strategies.
- To highlight the importance of genetic counseling and emerging reproductive technologies for managing MELAS inheritance.
- To underscore the potential of gene therapy for future MELAS treatment.
Main Methods:
- Review of existing literature on MELAS.
- Analysis of diagnostic criteria, including neuroimaging, laboratory findings (serum lactate), and muscle biopsy.
- Examination of current supportive care, attempted therapies, and future research directions like gene therapy.
Main Results:
- The A3243G mitochondrial DNA mutation is the predominant cause of MELAS.
- Diagnosis is supported by characteristic clinical, laboratory (elevated lactate), and muscle biopsy findings (mitochondrial proliferation).
- Current treatments are primarily supportive, with limited success from other therapeutic attempts.
Conclusions:
- MELAS is a significant maternally inherited disease primarily caused by the A3243G mitochondrial DNA mutation.
- Management involves supportive care, genetic counseling, and consideration of reproductive technologies to mitigate recurrence.
- Gene therapy research offers promising future treatment avenues for MELAS.
Related Concept Videos
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:22Mitral Valve Prolapse II: Assessment and Management